Your Source for Venture Capital and Private Equity Financings

Curebase Lands $40M Series B Round

SAN FRANCISCO, CA, Curebase, a company committed to democratizing access to clinical studies, has raised $40 million in Series B funding.
Curebase, a company committed to democratizing access to clinical studies, has raised $40 million in Series B funding to continue development of its end-to-end clinical trial execution model, virtual and hybrid site capabilities, and full eClinical software platform to run modern, patient-centric clinical trials. Since 2018, Curebase has established itself as a leader in decentralized clinical trials (DCTs) and patient-centric clinical trial software. This funding will deepen Curebase's breadth of capabilities beyond the virtual experience: via more complex site and community healthcare interfaces, a richer range of clinical software and services, and more robust capabilities for interventional drug sponsors and global studies.

Industry Ventures led this funding round, which included new institutional investors Acrew Capital, World Innovation Lab and Positive Sum, and existing investors GGV Capital, who led the Series A, Bold Capital and Xfund. The round also included a strategic investment by global biopharmaceutical company Gilead Sciences to deepen their partnership with Curebase on implementing DCT and hybrid capabilities in interventional trials.

In addition, Gaingels, an investment syndicate that focuses on startups dedicated to building diverse and inclusive teams participated in the round. Since its founding in 2017, Curebase has raised a total of $59 million.

Curebase is the leading provider of decentralized clinical research software and services, with the goal of powering research where any patient, anywhere can be part of clinical trials at home and with their own doctor. The Curebase platform enables any patient and any healthcare provider to be part of a clinical study, accelerating enrollment and enabling novel study designs with diverse populations. Curebase operates as a complete eClinical software platform and virtual research site with features including digital recruitment, ePRO, eCOA, telemedicine, eConsent, eSource, and more.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors

Featured Reading